Logos Global Management’s Keros Therapeutics KROS Stock Holding History

Logos Global Management’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-850,000	Closed	-$13.4M	–	78
2025 Q3	$13.4M	Sell	850,000 -1,150,000	-58%	-$17M	1.21%	32
2025 Q2	$26.7M	Hold	2,000,000	–	–	2.95%	8
2025 Q1	$20.4M	Buy	+2,000,000	New	+$23.2M	3.62%	8
2021 Q4	–	Sell	-15,000	Closed	-$593K	–	71
2021 Q3	$593K	Buy	+15,000	New	+$534K	0.04%	54
2021 Q1	–	Sell	-450,000	Closed	-$31.7M	–	64
2020 Q4	$31.7M	Sell	450,000 -1,150,000	-72%	-$72.5M	2.72%	8
2020 Q3	$61.7M	Buy	1,600,000 +1,200,000	+300%	+$47.6M	7.9%	2
2020 Q2	$15M	Buy	+400,000	New	+$12.3M	3%	14

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Logos Global Management's KROS Position: Q4 2025 in Review

Logos Global Management sold out of Keros Therapeutics (KROS) in Q4 2025, closing a stake of 850,000 shares — an estimated $13.4M sold.

Logos Global Management first reported a position in KROS in Q2 2020 and held it in 7 quarters. The position peaked at $61.7M in Q3 2020. 166 funds tracked by Wall St. Rank hold KROS as of Q4 2025.

Logos Global Management reported no remaining Keros Therapeutics position as of Q4 2025 after selling out during the quarter.
Logos Global Management sold 850,000 Keros Therapeutics shares in Q4 2025, an estimated $13.4M.
Logos Global Management first reported a position in Keros Therapeutics in Q2 2020 and held it in 7 quarters.
Logos Global Management's Keros Therapeutics position peaked at $61.7M in Q3 2020.
166 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2025.

Based on Logos Global Management's 13F filing for Q4 2025, filed 17 Feb 2026.